Oxidative Medicine and Cellular Longevity / 2020 / Article / Fig 1

Research Article

Nrf2 Inhibitor, Brusatol in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2-Positive Cancers by Inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 Pathways

Figure 1

Brusatol regressed the growth of HER2-positive SK-OV-3, BT-474, and SK-BR-3 cells by inhibiting Nrf2/HO-1 and HER2-AKT/ERK1/2 pathways. (a) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol in a dose range for 2 days. IC50 for BT-474, SK-OV-3, and SK-BR-3 were 0.7537 μM (95% confidence interval [CI], 0.6983–0.8136 μM), 0.7610 μM (95% CI, 0.6699–0.8646 μM), 8.631 μM (95% CI, 7.699–9.675 μM), respectively. Points, mean of 3 independent CCK-8 assays; bars, SD. (b) BT-474, SK-OV-3, and SK-BR-3 cells were treated with brusatol at 0, 1, 5, or 10 μM for 24 hours. The changes in Nrf2/HO-1 and HER2-AKT/ERK1/2 signaling pathways were monitored by western blotting.
(a)
(b)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.